In the cyclic peptide group, romidepsin, also named FK228 or depsipeptide, inhibits HDAC1 and HDAC2 and was the second HDAC inhibitor approved by the U.S. FDA to treat CTCL and PTCL. The gene discussed is HDAC1; the disease is mature T-cell and NK-cell non-Hodgkin lymphoma.